Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Immunic CEO talks BIO-Europe 2025, MS trials, and IMU-856

4:11
 
Share
 

Manage episode 518246059 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. The conversation centred on the progress of its lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for relapsing multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026. Vitt described the Vienna-based conference as “a very exciting, active, energetic meeting” and highlighted its international scope. He noted that while Immunic is US-focused, BIO-Europe provided valuable networking opportunities within the European investor and biotech community. Much of the investor and partner interest at the event was directed towards Immunic’s multiple sclerosis program. “It’s a unique growth story and has the ability to address here a multi-billion market opportunity,” said Vitt, referring to vidofludimus calcium, which he described as “a dual acting molecule” and “first in class Nurr-1 activator.” In addition, Vitt pointed to continued progress in Immunic’s gastrointestinal program, IMU-856, which has shown promising early clinical data in celiac disease and GLP-1 upregulation. The company is exploring further development and potential partnerships for this asset. For more biotech updates and executive insights, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel and enable notifications for future content. #Immunic #MultipleSclerosis #VidofludimusCalcium #IMU856 #BiotechNews #BIOEurope2025 #ClinicalTrials #PharmaUpdate #CeliacDisease #MSResearch #HealthcareInvesting
  continue reading

608 episodes

Artwork
iconShare
 
Manage episode 518246059 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. The conversation centred on the progress of its lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for relapsing multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026. Vitt described the Vienna-based conference as “a very exciting, active, energetic meeting” and highlighted its international scope. He noted that while Immunic is US-focused, BIO-Europe provided valuable networking opportunities within the European investor and biotech community. Much of the investor and partner interest at the event was directed towards Immunic’s multiple sclerosis program. “It’s a unique growth story and has the ability to address here a multi-billion market opportunity,” said Vitt, referring to vidofludimus calcium, which he described as “a dual acting molecule” and “first in class Nurr-1 activator.” In addition, Vitt pointed to continued progress in Immunic’s gastrointestinal program, IMU-856, which has shown promising early clinical data in celiac disease and GLP-1 upregulation. The company is exploring further development and potential partnerships for this asset. For more biotech updates and executive insights, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel and enable notifications for future content. #Immunic #MultipleSclerosis #VidofludimusCalcium #IMU856 #BiotechNews #BIOEurope2025 #ClinicalTrials #PharmaUpdate #CeliacDisease #MSResearch #HealthcareInvesting
  continue reading

608 episodes

Alla avsnitt

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play